Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.021x

Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥61.35 Million ≈ $8.98 Million USD) by net assets (CN¥2.87 Billion ≈ $419.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Chengdu Easton Biopharmaceuticals Co Ltd (688513) defensive interval to measure how many days the company can operate on defensive assets alone.

Chengdu Easton Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
TTW Public Company Limited BK:TTW	0.045x
Jutze Intelligent Technology Co Ltd SHE:300802	0.021x
Red Star Macalline Group Corp Ltd Class A SHG:601828	0.009x
Kestra Medical Technologies, Ltd. Common Stock NASDAQ:KMTS	-0.064x
Aurisco Pharmaceutical Co Ltd SHG:605116	N/A
Pennant Group Inc NASDAQ:PNTG	-0.009x
Reit 1 TA:RIT1	0.006x
Corbion NV AS:CRBN	0.155x

Annual Cash Flow Conversion Efficiency for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥6.66 Billion ≈ $975.13 Million	CN¥264.94 Million ≈ $38.77 Million	0.040x	-59.25%
2024-12-31	CN¥2.70 Billion ≈ $394.79 Million	CN¥263.24 Million ≈ $38.52 Million	0.098x	-7.71%
2023-12-31	CN¥2.60 Billion ≈ $380.96 Million	CN¥275.25 Million ≈ $40.28 Million	0.106x	+70.09%
2022-12-31	CN¥2.44 Billion ≈ $357.70 Million	CN¥151.94 Million ≈ $22.23 Million	0.062x	-3.49%
2021-12-31	CN¥2.29 Billion ≈ $335.34 Million	CN¥147.60 Million ≈ $21.60 Million	0.064x	-13.79%
2020-12-31	CN¥2.10 Billion ≈ $306.60 Million	CN¥156.52 Million ≈ $22.90 Million	0.075x	-63.26%
2019-12-31	CN¥697.44 Million ≈ $102.06 Million	CN¥141.83 Million ≈ $20.75 Million	0.203x	-29.02%
2018-12-31	CN¥582.19 Million ≈ $85.19 Million	CN¥166.79 Million ≈ $24.41 Million	0.286x	+48.85%
2017-12-31	CN¥445.28 Million ≈ $65.16 Million	CN¥85.70 Million ≈ $12.54 Million	0.192x	-29.27%
2016-12-31	CN¥389.79 Million ≈ $57.04 Million	CN¥106.06 Million ≈ $15.52 Million	0.272x	+44.32%
2015-12-31	CN¥268.21 Million ≈ $39.25 Million	CN¥50.57 Million ≈ $7.40 Million	0.189x	-17.97%
2014-12-31	CN¥203.25 Million ≈ $29.74 Million	CN¥46.71 Million ≈ $6.84 Million	0.230x	+37.82%
2013-12-31	CN¥168.62 Million ≈ $24.67 Million	CN¥28.12 Million ≈ $4.11 Million	0.167x	--

About Chengdu Easton Biopharmaceuticals Co Ltd

SHG:688513 China Biotechnology

Market Cap

$1.16 Billion

CN¥7.95 Billion CNY

Market Cap Rank

#8407 Global

#2063 in China

Share Price

CN¥45.01

Change (1 day)

+2.76%

52-Week Range

CN¥39.30 - CN¥79.60

All Time High

CN¥79.60